Biophan: Explosionsgefahr (Seite 4901)

[DausendUndMehr]

[posting]16.685.701 von DausendUndMehr am 23.05.05 08:39:13[/posting]schenke für noch ein e und ein r


wieder so eine Woche ...

[brasileiro58]

nur die, die beschichtet sind bzw. medikamente aus der beschichtung abgeben haben ein verfallsdatum.
sond übrigens news draussen:

Biophan CEO Michael Weiner to Present at 4th Annual NanoBusiness Conference 2005 in New York City; Company Chief to Outline High-Growth Business Strategy Based on Creation of Broadly Protective Patent Thickets
via COMTEX

May 23, 2005


Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation medical technology, will present an overview of its innovative nanotechnologies for the biomedical sector, and its high-growth business strategy to ensure growth through aggressive protection and enforcement of patents. Biophan CEO Michael Weiner will describe the Company`s nanotechnology solutions for multi-billion-dollar healthcare markets as a featured company at the 4th Annual NanoBusiness Conference 2005, to be held May 22 - 25, at the New York Marriott Financial Center, in New York, NY.

The four-day event will bring together leading nanotechnology companies and a range of guest speakers with a mix of scientific, investment, and industry experience. Delivering the keynote addresses are New York Senator Charles E. Schumer and Senator Ron Wyden.

Mr. Weiner will discuss the Biophan patent portfolio and its proprietary technologies in a half-hour presentation on May 25th, starting at 1:30 p.m. in the Grand ballroom.

"Biophan`s successful research and development program has already yielded a uniquely broad patent thicket in a number of advanced nanotechnology solutions in next-generation medical device and healthcare markets," said Mr. Weiner. "The business we`re in requires a strategy of both aggressive research and development, as well as protection of our proprietary biomedical and pharmaceutical industry solutions. Biophan has an unusually large intellectual property portfolio of more than 114 patents, applications, or licenses. This is a key component of the Company`s high-growth strategy to generate licensing revenues from several multi-billion-dollar areas of the healthcare industry."

For more information about the 4th Annual NanoBusiness Conference 2005, please visit: http://www.nanoevent.com/

About NanoBusiness 2005

NanoBusiness 2005 is nanotechnology`s foremost business conference, intended for key stakeholders in the business of small technology, and will again gather hundreds of CEOs, business leaders, investors, scientists and engineers for four intensive days of seminars, presentations, keynotes and networking events. NanoBusiness 2005 provides the information required to profit from the transformation of nanotechnology into nanobusiness.

[trickygirl]

[posting]16.686.200 von vanillaicebaer am 23.05.05 09:27:11[/posting]Wusste bisher gar nicht, dass stents ein Verfallsdatum haben.

[vanillaicebaer]

moin

BSX
FDA Approves 12-Month Shelf Life for Taxus(R) Stent System
New U.S. shelf life is longer than any competing product NATICK, Mass. - PRNewswire-FirstCall - May 23

NATICK, Mass., May 23 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE:BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in the United States to twelve months from the current shelf life of nine months. The decision was based on data submitted by Boston Scientific to the FDA that demonstrated the performance of the TAXUS system -- in particular the drug content, drug degradation profile and drug-release mechanism -- was maintained within FDA-approved specifications at twelve months. The new TAXUS U.S. shelf life is longer than any competing product.

The extended expiration date applies to all sizes of the TAXUS system for sale in the United States. The Company said it would immediately begin updating labels to reflect the twelve-month expiration date. The shelf life for the TAXUS system outside the United States remains unchanged at 18 months.

"The extended shelf life of TAXUS offers an additional benefit to physicians and other healthcare professionals making purchasing decisions for drug-eluting stents," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "The extended shelf life may facilitate inventory management for hospitals concerned with issues of stock rotation or product expiration."

[sportkegler]

eröff ffm 1,88

[DausendUndMehr]

Morgen

wie so eine Woche ...

[Demolitionman]

moin moni zusammen

[Bachalor]

werde bei shoetime wahrscheinlich noch nicht da sein.
wenn was ist mal bescheid sagen
daher vorweg

Its Showtime

[Bachalor]

den trittin konnte man ja gar nicht anhören.
frage mich immer wieder wo die soviele stimmen herbekommen
die in der berliner runde von den grünen war ja auch so ein kaliber

[Bachalor]

Morgen

Licht an!!!